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alternative. CONCLUSION: Under all circumstances, strategies
using PPIs are optimal for managing patients with GERD.
Emerging concerns around hip fracture and AMI do not signiﬁ-
cantly affect the relative cost-effectiveness performance of alter-
native treatment strategies.
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OBJECTIVE: To determine the cost-utility of PPIs, compared to
alternative gastrointestinal prophylaxis, in the prevention of
GI complications among elderly patients (age  65) taking
nsNSAIDs. METHODS: A cost-utility analysis, from a third-
party payer perspective, was conducted using a decision analy-
tical model over a one year time horizon. We compared:
nsNSAID alone, nsNSAID + PPI (omeprazole, 20 mg od),
nsNSAID + ranitidine (150 mg bid), nsNSAID + ranitidine
(300 mg bid), misoprostol (200 ug bid), and misoprostol
(200 ug qid). Clinical inputs (including ulcer risk, bleeding com-
plications, dyspepsia symptoms), costs, and utilities were derived
from recently published studies. Probabilistic and deterministic
sensitivity analyses were performed to test the robustness of the
results. RESULTS: In elderly patients’ aged 65 y, the incremen-
tal cost-utility ratio (ICUR) of PPIs, relative to nsNSAID alone,
was $320,743 per Quality-adjusted life year (QALY) gained.
Other treatment alternatives (ranitidine and misoprostol) were
dominated. The ICUR of PPI, relative to nsNSAID alone, was
$207,604 per QALY gained in patients aged >75 y. In patients
taking concomitant low-dose aspirin, ICURs for PPI therapy
were $190,943 and $117,944 per QALY gained in patients’ aged
65 y and aged75 y, respectively. In patients’ aged65 y with
a history of a complicated or uncomplicated ulcer, ICURs of
$25,662 and $45,688 were observed, respectively. CONCLU-
SION: Routine prescription of PPIs in all elderly patients (age
65 y) taking nsNSAIDs may not be warranted in a health care
system with ﬁnite resources, as ICURs exceeded commonly cited
thresholds in the range $50,000–$100,000 per QALY gained.
However, co-prescribing PPIs among all elderly patients (age
65 y) taking nsNSAIDs and with a history of a complicated or
uncomplicated ulcer may be considered good value for money,
as ICURs are less than $50,000 per QALY gained.
GASTROINTESTINAL DISORDERS—
Patient-Reported Outcomes
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OBJECTIVE: Examine medication utilization for gastro-
esophageal reﬂux disease (GERD) in a community-based setting.
Assess disparities in types of medications used and frequency of
use related to severity of symptoms, race, education, employ-
ment, and income. METHODS: A questionnaire based upon
previous work (Srinivansin, J Clin Gastro) was developed to
assess self-reported GERD prevalence and medication utilization
and was translated into Chinese and Spanish. We worked with
community and faith-based leaders to identify events for data
collection. GERD prevalence and medication usage in four ethnic
groups (White, Black, Asian, Hispanic) were compared, control-
ling for age, gender and other demographic variables. Descriptive
and multivariate analyses were done using SAS 9.1. RESULTS:
Of the 34.6% (307/1172) of respondents reporting at least
weekly heartburn, 60.6% took over-the-counter medication,
56.4% took prescription (Rx) medication and 12.7% took no
medications. Whites had a signiﬁcantly higher rate of OTC uti-
lization at 68.8%, followed by Hispanics, Blacks, and Asians at
61.1%, 60.2%, and 35.5%, respectively (P = 0.0127). Whites
were the lowest utilizers of Rx medications compared to the
other ethnicities. For those taking prescription Proton Pump
Inhibitors (PPIs), (N = 131) 51.7% took them 5 to 7 times per
week. Participants with at least weekly and daily heartburn were
more likely to take PPIs 5–7 times per week (P = .0098 and
P = 0.0056, respectively). Subjects with a diagnosis of GERD by
a physician were more likely to take their prescription PPIs 5 to
7 times per week compared to those claiming no diagnosis, 60%
v. 37.3%, respectively (P = 0.0111). CONCLUSION: We found
signiﬁcant variation in the use of OTC and RX medications for
GERD by ethnicity. Only half of patients taking prescription PPIs
took them 5–7 times per week. Future research should focus on
improving communication of GERD diagnosis to patients and
recommended use of prescription PPIs in the absence of a diag-
nosis for GERD.
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OBJECTIVE: Several biologics, especially TNF antagonists, have
been established as effective therapy for Crohn’s disease (CD).
Adherence to biologic therapy is thought to be important for
optimal outcomes. This analysis retrospectively quantiﬁed the
impact of non-adherence to inﬂiximab maintenance therapy on
medical service use by CD patients. METHODS: CD patients on
inﬂiximab maintenance therapy were identiﬁed from the Inte-
grated Healthcare Information Services claims database (cover-
ing approximately 35 million managed care lives from January 1,
1999 to June 30, 2006) if they had 4 inﬂiximab infusions (with
intervals 12 weeks between the ﬁrst four infusions) in the ﬁrst
year following inﬂiximab initiation. Non-adherence was deﬁned
as total number of inﬂiximab infusions <7 in the ﬁrst year (the
expected number is 8 if patients follow the labeled schedule).
One-year medical service utilization and costs (excluding inﬂix-
imab drug/administration costs) were analyzed. Descriptive sta-
tistics and multivariate regressions adjusted for confounders
were performed. RESULTS: A total of 647 CD patients were
identiﬁed. The 1-year non-adherence rate was 35.9%. Descrip-
tive statistics demonstrated that non-adherent patients were
more frequently hospitalized, and incurred greater 1-year costs
for hospitalization and total medical services (p = 0.05 for all
comparisons). Adjusted multivariate regression analyses demon-
strated that, compared with adherent patients, non-adherent
patients had greater risks of hospitalization (odds ratios were
2.3 for CD-related; 2.5 for all-cause, both p < 0.001); and
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incurred greater costs for hospitalization (additional $7767 for
CD-related, $9417 for all-cause; both p = 0.001), outpatient
visits (additional $1025 for CD-related, p < 0.001; $1307 for
all-cause, p = 0.003), and total medical services (additional
$5236 for CD-related and $6953 for all-cause, both p < 0.001).
CONCLUSION: More than one-third of the CD patients on
inﬂiximab maintenance therapy in the cohort were non-adherent
to therapy within 1 year. Non-adherence was associated with
greater medical service utilization and costs.
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OBJECTIVE: The Inﬂammatory Bowel Disease Questionnaire
(IBDQ) is a valid, reliable, and sensitive measure to assess
patients’ subjective health status and quality of life (QOL). Prior
to its use in an international clinical trial of active Ulcerative
Colitis, the 32-item IBDQ underwent linguistic validation in 35
languages or cultures, including 8 Indian languages. METHODS:
For languages with no prior translation, the Canadian English
original was translated by specialists in each target country fol-
lowing a standardized methodology: 1) two independent forward
translations were done by professional translators, native speak-
ers of the target language and ﬂuent in English; 2) comparison
with the original and reconciliation of translations by the target
country specialist were made; 3) backward translation was per-
formed by a native English speaker; 4) comparison of source and
backtranslations were reviewed with the IBDQ developer; 5)
comprehension testing of 5 patients with moderately to severely
active Ulcerative Colitis was performed. Pre-existing translations
were integrated into the process as appropriate. RESULTS: Lin-
guistic and conceptual challenges emerged in translating the
7-point Likert scale response choices (RC). Literal translation of
the original 7-point RCs was not suitable in all languages.
Anchors were chosen to be comparable to the original; the ﬁve
middle response choices were logical and equidistant from one
another. Some wording adaptation was needed for most coun-
tries to reﬂect local idiomatic expressions; particularly, “bowel
movements” required more precise translation in most lan-
guages. CONCLUSION: The 35 language versions of the IBDQ
were established using a rigorous process to ensure conceptual
harmonization that would permit international comparisons and
data pooling. The IBDQ may now be used conﬁdently in these
countries to evaluate the impact of inﬂammatory bowel disease
on patients’ daily lives.
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OBJECTIVE: Diarrhea without infectious etiology (episodic,
chronic) is reported in excess of 20% of HIV/AIDS patients
receiving standard of care HAART therapy. Diarrhea of any
severity and/or frequency negatively affects health-related quality
of life (HRQoL) for these individuals. No instrument speciﬁc to
the impact of HIV/AIDS-related diarrhea currently exists. To
measure a HRQoL beneﬁt from a new oral antidiarrheal in
clinical testing, a new PRO instrument is being developed.
METHODS: Comprehensive review of the HRQoL literature of
diarrhea in the general and HIV/AIDS populations was con-
ducted and experts in HIV and GI medicine were interviewed.
Focus groups of HIV+ individuals experiencing diarrhea were
undertaken. The psychometric properties of the draft question-
naire items were evaluated from data collected via the Internet in
320 respondents. Also collected within the cross-sectional, devel-
opment study were respondent demographics, bowel movement
history, SF-12, and Work Productivity & Activity Impairment
(WPAI) questionnaire. Following item reduction, content validity
was evaluated by cognitive debrieﬁng. RESULTS: Literature
review, expert feedback, and focus groups informed the concep-
tual model and construction of 41 draft questions regarding
HRQoL related to chronic diarrhea among HIV+ individuals.
Item reduction was achieved by exploratory and conﬁrmatory
factor analyses and conﬁrmed a one-factor best ﬁt model. A
generalized, partial credit IRT analysis facilitated further item
reduction. Differential item functioning analyses conﬁrmed no
signiﬁcant differences in item performance among subgroups
tested. Convergent and discriminate validity were supported by
correlations with SF-12 scales, WPAI and self-reported symptom
frequency and severity scores (correlation coefﬁcients 0.58 to
0.71), and analysis of variance among clinically deﬁned diarrhea
severity (F = 32, p < 0.0001, ç2 0.17). CONCLUSION: A newly
developed survey assessing the impact of chronic diarrhea on
HIV+ patients has demonstrated acceptable psychometric prop-
erties. The survey will be validated in a double-blind, placebo-
controlled diarrhea treatment study.
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OBJECTIVE: To describe gastroesophageal reﬂux disease
(GERD) patients who are partial responders to treatment of
proton pump inhibitors (PPI) in terms of their health care utili-
zation, quality of life and work productivity. METHODS: The
analysis is based on the National Health and Wellness Survey
(NHWS) conducted by the Consumer Health Sciences (CHS) in
USA 2006. Partial responders are deﬁned as diagnosed GERD
patients with remaining at least moderate symptoms 4 times/
week or more after two months PPI-treatment (n = 1433). This
group is compared to 1) GERD patients with only mild symp-
toms or moderate to severe symptoms less than 4 times/week
after a short course of PPI treatment (n = 281), and 2) all indi-
viduals, excluding partial responders, who self-reported GERD,
(n = 19,817). RESULTS: Partial responders use PPI on average
24.5 days/month which is 7.4 days more than patients respond-
ing well and 1.2 days more than all GERD patients. The SF-8
physical summary score is 38.6 for partial responders, which is
5.3 points less than for patients responding well and 7.4 points
less than for all GERD patients. The mental summary score for
partial responders is 41.9 which is 4.3 and 4.6 points less for
patients responding well and all GERD patients, respectively.
Partial responders lost 10.9 hours per week due to reduced
productivity at work, which is 2.4 hours more than for patients
responding well and 3.8 hours more than for all GERD patients.
Partial responders consume resources and impose total produc-
tivity losses equivalent to $2603 per month, which is $724 more
than for patients responding well and $1162 more than for
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